In a patient with obstructive sleep apnea who is adherent to CPAP with adequate usage and low residual AHI but continues to have excessive daytime somnolence, what are the next steps in evaluation and management?

Residual Excessive Daytime Sleepiness Despite Optimal CPAP

For patients with persistent excessive daytime sleepiness despite adherent CPAP use with low residual AHI, wake-promoting pharmacotherapy with solriamfetol is the recommended next step after excluding other causes of sleepiness. 1, 2

Initial Evaluation Steps

Before initiating pharmacotherapy, you must systematically exclude other causes of persistent somnolence:

Rule Out Technical CPAP Issues

• Verify actual CPAP adherence data (not just patient report): minimum 4 hours/night is inadequate for many patients
• Confirm residual AHI is truly <5 events/hour (not just <10)
• Check for mask leak, mouth breathing, or pressure intolerance
• Review download data for persistent respiratory events despite "adequate" settings 3

Screen for Comorbid Sleep Disorders

• Insomnia (COMISA): Present in significant proportion of OSA patients and worsens daytime function
• Circadian rhythm disorders: Delayed sleep phase, shift work disorder
• Restless legs syndrome/periodic limb movements: Can fragment sleep despite controlled OSA
• Narcolepsy or idiopathic hypersomnia: May coexist with OSA
• Consider objective testing (MSLT, MWT) when diagnosis is unclear, though these should not be used independently for diagnosis 1

Assess Medication and Lifestyle Factors

• Review sedating medications (benzodiazepines, antihistamines, opioids, antipsychotics)
• Evaluate alcohol use, cannabis use
• Screen for insufficient sleep syndrome (inadequate time in bed)
• Assess sleep hygiene practices 2

Evaluate Medical Comorbidities

• Hypothyroidism: Check TSH
• Depression/anxiety: Use validated screening tools
• Obesity hypoventilation syndrome: Check daytime CO₂ if BMI >35
• Cardiovascular disease, diabetes: May contribute to fatigue independent of OSA 4

Quantify Residual Sleepiness

Use the Epworth Sleepiness Scale (ESS) as your primary assessment tool:

• ESS ≥10 indicates clinically significant excessive daytime sleepiness
• Minimum clinically important difference is 2-3 points for monitoring treatment response
• Reassess at each follow-up 1

The Karolinska Sleepiness Scale (KSS) or Stanford Sleepiness Scale (SSS) can supplement but should not replace ESS 1.

Pharmacological Management

First-Line Wake-Promoting Agents

Solriamfetol is the preferred agent based on the most recent evidence for both residual EDS despite adequate CPAP and for patients refusing/intolerant of CPAP 1, 2. The 2025 Chinese expert consensus specifically recommends solriamfetol with the highest level of evidence (1, A) for both scenarios.

Modafinil is an alternative option with strong evidence for residual EDS in CPAP-adherent patients (1, A), but has lower-quality evidence (2, B) for patients not using CPAP 1, 2.

Pitolisant may be considered, particularly in patients with cardiovascular risk factors where other stimulants are concerning, though it has slightly less robust evidence in some guidelines 5, 1.

Key Prescribing Considerations

When initiating wake-promoting agents, you must:

1. Document clear indication: Patient meets criteria of either (a) residual EDS despite adequate CPAP adherence with low residual AHI and other causes excluded, OR (b) clinically significant EDS with refusal/intolerance of CPAP 1, 2

2. Screen cardiovascular risk: These agents can increase blood pressure and heart rate. Exercise caution in patients with uncontrolled hypertension, arrhythmias, or recent cardiovascular events 1

3. Monitor for dependence risk: Particularly with modafinil and traditional stimulants 1

4. Continue encouraging CPAP: Even when treating EDS pharmacologically in non-adherent patients, continue counseling about resuming standard OSA therapy 2

5. Regular follow-up: Monitor efficacy with ESS and assess for adverse effects at regular intervals 1

Agents NOT Recommended

• Methylphenidate and dextroamphetamine: Insufficient evidence for OSA-related EDS 1
• Mirtazapine, paroxetine, protriptyline: Inadequate evidence as primary OSA treatments 4

Emerging Therapies

Recent evidence suggests potential roles for:

• Orexin-2 receptor agonists: Direct wake-promoting effect, currently under investigation 6
• GLP-1/GIP receptor agonists (tirzepatide): For OSA patients with obesity who have inadequate response to lifestyle interventions, may reduce both OSA severity and associated sleepiness 2, 6

Common Pitfalls to Avoid

1. Accepting "adequate" CPAP based solely on 4 hours/night: Many patients need more hours for symptom resolution 7

2. Missing comorbid insomnia: COMISA is extremely common and requires specific management—consider short-term non-benzodiazepine hypnotics if needed, but avoid benzodiazepines 2

3. Prescribing wake-promoting agents without excluding reversible causes: Always rule out technical CPAP issues, insufficient sleep time, and sedating medications first 8

4. Using pharmacotherapy as monotherapy in non-adherent patients without continued CPAP counseling: The goal remains treating the underlying OSA 2

5. Failing to reassess: Residual sleepiness may evolve; regular monitoring with ESS and objective adherence data is essential 9

Management Algorithm

Step 1: Verify true CPAP optimization (download data showing >6 hours/night, residual AHI <5, minimal leak)

Step 2: Exclude other causes (comorbid sleep disorders, medications, insufficient sleep, medical conditions)

Step 3: Quantify sleepiness with ESS (threshold ≥10)

Step 4: If ESS ≥10 persists after Steps 1-2, initiate solriamfetol (or modafinil as alternative)

Step 5: Monitor response with ESS at 1 month (expect 2-3 point reduction as meaningful improvement)

Step 6: Screen for cardiovascular and psychiatric adverse effects at each visit

Step 7: Continue long-term follow-up every 3-6 months with reassessment of CPAP adherence and consideration of emerging comorbidities

The prevalence of residual EDS despite optimal CPAP ranges from 12-58% in various studies 8, making this a common clinical scenario requiring systematic evaluation and evidence-based pharmacological intervention when appropriate.